The 26th edition of the Tour Charles-Bruneau concluded on July 8. The cyclists were welcomed in an energetic atmosphere to close this edition of the Tour CIBC Charles-Bruneau.

By cycling one of the 12 routes, up to 800 km, the participants raised a total of $4,100,000 for a cause close to their hearts, namely all children with cancer in Quebec. Thanks to their mobilization and the generosity of the public, the Charles-Bruneau Foundation will be able to continue to fund important research projects in pediatric hemato-oncology. Once again, the Tour CIBC Charles-Bruneau was a success and all the people who contributed can be proud of having embodied the event's mission: together towards a childhood without cancer!

BLG-20220714-CIBC-Image-1

True sources of inspiration

The Charles-Bruneau Foundation would also like to thank the 70 children paired with the participating cyclists and the six-course heroes who kindly agreed to get involved this year. Their stories are a beacon of hope, an example of resilience and a source of inspiration that encourage and motivate participants to pedal year after year.

IRIS has been involved with the Charles Bruneau Foundation for 20 years. Eric Babin, President of IRIS, accompanied by IRIS employees, is involved as a cyclist and an ardent ambassador of the Charles Bruneau Foundation by mobilizing IRIS team members to do various activities to raise donations.

The amount raised through this 26th edition of the Tour CIBC Charles-Bruneau is significant. It proves that despite the two years of pandemic that we have just gone through, the Tour still has a place in the hearts of various partners such as IRIS and donors and participants.

BLG-20220714-CIBC-Image-2

This money will be used to finance projects in immuno-hemato-oncology, where eminent researchers are preparing the medicine of tomorrow. Two goals guide the researchers: to cure the 20% of children whose cancer is resistant to treatment and to improve the quality of life of children in remission to achieve a true cure without sequelae or complications.

IRIS is proud to invest in pediatric cancer research so that every child can one day say: "When I grow up, I will be cured."